NCT06998771View on ClinicalTrials.gov

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2029

Conditions
HER2-positive Gastric Cancer
Interventions
DRUG

JSKN003

JSKN003 is administered by intravenous infusion.

DRUG

KN026

KN026 is administered by intravenous infusion.

DRUG

Capecitabine

Capecitabine is for oral administration.

DRUG

Enlonstobart

Enlonstobart is administered by intravenous infusion.

DRUG

Oxaliplatin

Oxaliplatin is administered by intravenous infusion.

DRUG

Trastuzumab

Trastuzumab is administered by intravenous infusion.

DRUG

Pembolizumab

Pembolizumab is administered by intravenous infusion.

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY